Eli Lilly vs Pfizer: One Owns the Obesity Market Today, The Other Paid to Compete Tomorrow24/7 Wall Street • 06/22/26
Doctors say that GLP-1 medications can prevent lifelong obesity and Type 2 diabetes in children—but there are some worriesWSJ • 06/22/26
Pfizer's Dividend Yield is 10X Bigger Than Eli Lilly's. Does That Make It the Better Stock for Income Investors?The Motley Fool • 06/20/26
Lilly's 7 Acquisitions in 3 Months: Which Will Be the Biggest Game-Changer for the Pharma Giant?The Motley Fool • 06/20/26
Vertex Has a Head Start in Non-Opioid Pain. Eli Lilly Just Spent Billions to Catch Up.The Motley Fool • 06/20/26
Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should KnowZacks Investment Research • 06/18/26
Can Pfizer Take Share From Lilly & Novo Nordisk in the Obesity Space?Zacks Investment Research • 06/18/26
Eli Lilly Takes Another Stab at the Market for Painkillers. This Attempt Might Work.Barrons • 06/16/26
Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLLPRNewsWire • 06/14/26
Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual MeetingPRNewsWire • 06/13/26
Eli Lilly Stock Hits Buy Zone As Earnings Soar 156%. Funds Are Loading Up.Investors Business Daily • 06/12/26
Pfizer's New Weight-Loss Data Just Gave Eli Lilly and Novo Nordisk Investors Something to Worry AboutThe Motley Fool • 06/12/26
Forget Eli Lilly and Company: As June Volatility Rocks High-Flyers, This Stock Is a No-Brainer Buy24/7 Wall Street • 06/12/26